Research output per year
Research output per year
Personal profile
About
Dr. Lourens T. Bloem (PharmD, MSc) is an assistant professor at the Division of Pharmacoepidemiology and Clinical Pharmacology of the Utrecht Intstitute for Pharmaceutical Sciences, Utrecht University.
He aims to optimise outcomes of medicines in patient care through interdisciplinary research, integrating drug regulatory science (evaluation and improvement of regulatory decision-making), clinical pharmacology (optimal clinical use of medicines), and (pharmaco-)epidemiology ('real-world' effects of medicines). He focuses on innovative medicines for patients with cancers and rare diseases for which unmet medical needs are typically highest. As such, he is involved in several research and infrastructural consortia, including DARE-NL, Oncode Accelerator, and CURE4LIFE.
At Utrecht University, Lourens is a member of the Utrecht Young Academy, the Faculty Open Science Team (Faculty of Science), and the Board of Examiners of the MSc Pharmacy programme.
Furthermore, he chairs the special interest groups Cell and Gene Therapy of the International Society for Pharmacoepidemiology (ISPE) and Advanced Therapies of the Regulatory Science Network Netherlands (RSNN). In addition, he is strategic liaison between ISPE and the European Society for Medical Oncology (ESMO), member of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT (formerly the European Society for Blood and Marrow Transplantation), member of the Multi-stakeholder board of the national cell and gene therapy network of the Netherlands, ATMP-NL, and member of the Committee ATMP of the Dutch Medicines Evaluation Board.
Research interests
Scientific disciplines: Pharmacoepidemiology, Clinical pharmacology, Drug regulatory science
Therapeutic domains: Oncology, Rare diseases
Pharmacological treatments: Cell and gene therapies, Advanced therapies, Innovative medicines
Other: Uncertainty, Unmet medical need, and their role in decision-making and communication
Link to Utrecht University staff page
Education/Academic qualification
University Teaching Qualification (UTQ), Dept of Pharmaceutical Sciences
Award Date: 2 Oct 2023
PhD (Drug Innovation PhD Programme), Pharmacoepidemiology and Clinical Pharmacology
Award Date: 24 Nov 2021
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Lourens T. Bloem is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Publication network from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study
Brinkhuis, F., Goettsch, W. G., Mantel - Teeuwisse, A. & Bloem, L. T., 28 Feb 2024, In: The BMJ. 384, 12 p., e077391.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Long-term follow-up after authorization of gene therapy: leveraging real-world data
de Haart, K., Asao, K., Ataher, Q., Geier, J., Hillen, J., Huang, K., Mol, P. G. M., Rivera, D., Wang, H., Yang, H., Zhan, S., Hoogendoorn, W. E. & Bloem, L. T., May 2025, In: Drug Discovery Today. 30, 5, 104337.Research output: Contribution to journal › Review article › peer-review
Open AccessFile -
Patient preferences and attitudes regarding the environmental impact of medicines: A discrete choice experiment
Sadreghaemy, M., Philbert, D., Heerdink, E. R., Bouvy, M. L., Egberts, T. C. G. & Bloem, L. T., Oct 2025, In: British Journal of Clinical Pharmacology. 91, 10, p. 2771-2781 11 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy
Verschueren, M. V., Peters, B. J., Bloem, L. T., Kruik, V. R., Uitvlugt, E. B., Bijsmans, A. R., Egberts, A. C. & van de Garde, E. M., Mar 2024, In: Clinical Lung Cancer. 25, 2, p. 119-127.e1Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Regulatory and Health Technology Assessment of ATMPs in the European Union: Towards Patient Access
Bloem, L. T., Fabriek, B. O., Schiel, A. & ten Ham, R. M. T., 30 Apr 2026, Springer Handbook of Medical Biotechnology. Silva, A. C. (ed.). Cham: Springer Nature Switzerland, p. 681-712 32 p. (Springer Handbooks; vol. Part F1789).Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review
In the media
-
Talk: Dr. Lourens Bloem over de wereld van geneesmiddelen en het zorgsysteem
13/11/25
1 Media contribution
Press/Media: Expert Comment